A role for mesenchymal stem cells in the control of graft-versus-host disease.
Several reports have demonstrated the ability of mesenchymal stem cells (MSCs) to enhance hemopoietic engraftment and to exert a profound inhibitory effect on T-cell proliferation in vitro, making them a candidate for the prevention/treatment of graft-versus-host disease. Recent publications have highlighted the underlying mechanisms of the immunosuppressive function of MSCs, elicited by proinflammatory cytokines, such as interferon-gamma and tumor necrosis factor-alpha. These new findings have lead to a better understanding of the biology of MSCs, the outcome of graft-versus-host disease clinical trials and the conflicting results of preclinical T-cell-dependent pathologies. The potential use of MSCs as immunosuppressive elements in allogeneic stem-cell transplantation settings is thus discussed below.
Université Pierre et Marie Curie-Paris 6, CNRS, UMR, Paris, France. jose.cohen@chups.jussieu.fr
José L
JL
Cohen
Muriel
M
Sudres
D002986:Clinical Trials as Topic; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D008213:Lymphocyte Activation; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma